Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Near-term sentiment is focused on the upcoming XP-8121 program webinar, which serves as a key pipeline catalyst, alongside recent analyst rating adjustments.
Xeris will host a webinar to detail the Phase 3 development program for XP-8121, its once-weekly subcutaneous levothyroxine injection for hypothyroidism. The event will include clinical development plans and commercial opportunity analysis, serving as a significant pipeline catalyst for investors.
Xeris Biopharma Press ReleaseWall Street Zen recently downgraded Xeris Biopharma to a "Hold" rating. This adjustment reflects potential caution regarding the company's path to profitability despite strong top-line revenue growth.
American Banking News